Daniel L. Mulkerin, MD close
Daniel L. Mulkerin, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Daniel L. Mulkerin, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Daniel Mulkerin, MD graduated from Jefferson Medical College. He then completed residency in Internal Medicine and Fellowship in Medical Oncology at the University of Wisconsin Hospital and Clinics. Dr. Mulkerin joined the UW Medical School faculty in 1999 and is currently an Assistant Professor in the Department of Medicine, Section of Medical Oncology. His clinical expertise is in the treatment of gastrointestinal malignancies, including liver and pancreas esophageal, stomach, biliary, colon, rectal and anal cancers. He is actively involved in the development of new therapies for patients with these diseases. Dr. Mulkerin also serves as Regional Director of the University of Wisconsin Carbone Cancer Center regional cancer center network, which includes affiliate sites in eight communities within Wisconsin and Illinois.



UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
University Hospital
(608) 263-7502 | (800) 323-8942 | Map
University Hospital
(608) 263-7502 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, PA

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
PubMed Articles
Uboha NV Lubner SJ LoConte NK Mulkerin DL Eickhoff JC Deming DA Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors. Invest New Drugs . 2020 Oct;38(5):1520-1525
[PubMed ID: 32253554]
Witt JS Kuczmarska-Haas A Lubner M Reeder SB Cho SY Minter R Weber S Ronnekleiv-Kelly S Abbott D LoConte N Mulkerin DL Lubner SJ Uboha NV Deming D Ritter MA Mohindra P Bassetti MF A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys . 2020 Sep 14;
[PubMed ID: 32942002]
Sugalski JM Kubal T Mulkerin DL Caires RL Moore PJ Fiorarancio Fahy R Gordon JN Augustyniak CZ Szymanski GM Olsen M Frantz DK Quinn MA Kidd SK Krause DM Carlson RW Stewart FM National Comprehensive Cancer Network Infusion Efficiency Workgroup Study: Optimizing Patient Flow in Infusion Centers. J Oncol Pract . 2019 May;15(5):e458-e466
[PubMed ID: 30964732]
Jared JR Mably MS Makielski R Reed MP Fallon MJ Liu G Mulkerin D Callander NS Utilization and evaluation of noncore chemotherapy regimens within an academic medical center. J Oncol Pharm Pract . 2017 Oct;23(7):518-524
[PubMed ID: 27388159]
Venook AP Niedzwiecki D Lenz HJ Innocenti F Fruth B Meyerhardt JA Schrag D Greene C O'Neil BH Atkins JN Berry S Polite BN O'Reilly EM Goldberg RM Hochster HS Schilsky RL Bertagnolli MM El-Khoueiry AB Watson P Benson AB 3rd Mulkerin DL Mayer RJ Blanke C Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA . 2017 Jun 20;317(23):2392-2401
[PubMed ID: 28632865]
Mulkerin DL Bergsbaken JJ Fischer JA Mulkerin MJ Bohler AM Mably MS Multidisciplinary Optimization of Oral Chemotherapy Delivery at the University of Wisconsin Carbone Cancer Center. J Oncol Pract . 2016 Oct;12(10):e912-e923
[PubMed ID: 27858570]
Sievers CK Kratz JD Zurbriggen LD LoConte NK Lubner SJ Uboha N Mulkerin D Matkowskyj KA Deming DA The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms. Clin Colon Rectal Surg . 2016 Sep;29(3):232-8
[PubMed ID: 27582648]
Jin N Lubner SJ Mulkerin DL Rajguru S Carmichael L Chen H Holen KD LoConte NK A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors. Oncologist . 2016 Jul;21(7):785-6
[PubMed ID: 27261467]
Deming DA Cavalcante LL Lubner SJ Mulkerin DL LoConte NK Eickhoff JC Kolesar JM Fioravanti S Greten TF Compton K Doyle AG Wilding G Duffy A Liu G A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest New Drugs . 2016 Apr;34(2):168-75
[PubMed ID: 26666244]
Wisinski KB Ledesma WM Kolesar J Wilding G Liu G Douglas J Traynor AM Albertini M Mulkerin D Bailey HH A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract . 2015 Dec;21(6):416-24
[PubMed ID: 24986793]
Tran NH Cavalcante LL Lubner SJ Mulkerin DL LoConte NK Clipson L Matkowskyj KA Deming DA Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol . 2015 Sep;7(5):252-62
[PubMed ID: 26327923]
Makielski RJ Lubner SJ Mulkerin DL Traynor AM Groteluschen D Eickhoff J LoConte NK A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. Cancer Chemother Pharmacol . 2015 Aug;76(2):317-23
[PubMed ID: 26068189]
LoConte NK Razak AR Ivy P Tevaarwerk A Leverence R Kolesar J Siu L Lubner SJ Mulkerin DL Schelman WR Deming DA Holen KD Carmichael L Eickhoff J Liu G A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs . 2015 Feb;33(1):169-76
[PubMed ID: 25318436]
LoConte NK Holen KD Schelman WR Mulkerin DL Deming DA Hernan HR Traynor AM Goggins T Groteluschen D Oettel K Robinson E Lubner SJ A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs . 2013 Aug;31(4):943-8
[PubMed ID: 23263993]
Leal TB Remick SC Takimoto CH Ramanathan RK Davies A Egorin MJ Hamilton A LoRusso PA Shibata S Lenz HJ Mier J Sarantopoulos J Mani S Wright JJ Ivy SP Neuwirth R von Moltke L Venkatakrishnan K Mulkerin D Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol . 2011 Dec;68(6):1439-47
[PubMed ID: 21479634]
Mohammed TA Holen KD Jaskula-Sztul R Mulkerin D Lubner SJ Schelman WR Eickhoff J Chen H Loconte NK A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist . 2011;16(6):835-43
[PubMed ID: 21632454]
Lubner SJ Kunnimalaiyaan M Holen KD Ning L Ndiaye M Loconte NK Mulkerin DL Schelman WR Chen H A preclinical and clinical study of lithium in low-grade neuroendocrine tumors. Oncologist . 2011;16(4):452-7
[PubMed ID: 21393344]
Leal T Tevaarwerk A Love R Stewart J Binkley N Eickhoff J Parrot B Mulkerin D Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer. Clin Breast Cancer . 2010 Dec 1;10(6):471-6
[PubMed ID: 21147691]
Lubner SJ Loconte NK Holen KD Schelman W Thomas JP Jumonville A Eickhoff JC Seo S Mulkerin DL A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. Clin Colorectal Cancer . 2010 Jul;9(3):157-61
[PubMed ID: 20643620]
Attia S Morgan-Meadows S Holen KD Bailey HH Eickhoff JC Schelman WR Traynor AM Mulkerin DL Campbell TC McFarland TA Huie MS Cleary JF Tevaarwerk AJ Alberti DB Wilding G Liu G Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol . 2009 Jun;64(1):45-51
[PubMed ID: 18841362]